Recruiting
Phase 1
Phase 2

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Sponsor:

Pediatric Brain Tumor Consortium

Code:

NCT04201457

Conditions

Low Grade Glioma (LGG) of Brain With BRAF Aberration

High Grade Glioma (HGG) of the Brain With BRAF Aberration

Low Grade Glioma of Brain With Neurofibromatosis Type 1

Eligibility Criteria

Sex: All

Age: 1 - 30

Healthy Volunteers: Not accepted

Interventions

Dabrafenib

Trametinib

Hydroxychloroquine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information